2 results
Approved WMOCompleted
The primary objective is to evaluating the impact of treatment on subject reported outcomes of their satisfaction and experience of treatment with VOLUMA® with Lidocaine (2ml or 1ml or a combination of both), for the mid-face area volume enhancement…
Approved WMORecruiting
To determine the objective response rate of entrectinib, as assessed by BICR, in each patient population basket of solid tumors that harbor anNTRK1/2/3, ROS1, or ALK gene rearrangement